Pancreatic cancer, including cancers that are difficult to treat. It is seen from at least the development of effective chemotherapeutic drugs for cancers. Gemcitabine is the standard therapy and has been recommended. The problem is, after progression with gemcitabine achieved, not many treatment options is recommended, even NCCN recommends to get therapy clinical trials are being conducted. In addition, the choice of second-line therapy, ie capecitabine, 5-fluorouracil/leucovorin/oxaliplatin, or a combination regimen of capecitabine / oxaliplatin.
A retrospective study conducted recently on 30 the subject of people with pancreatic cancer in order to assess the benefits and tolerability of weekly cycles of paclitaxel as second-line therapy for patients with pancreatic cancer refractory to gemcitabine. Paclitaxel administered in doses of 80 mg/m2 per week (for 3
weeks, rest 1 week). Therapy given to achieve progressivity. The result: the median number of cycles of 8 (range between 1-22 cycles), the median life expectancy of 6.7 months, 10% therapeutic response, disease control rate of 46.7%, and the side effects of degrees 3-4 (hematologic and non-hematologic) 23%. Side effects that occur can usually be treated with conservative therapy. There is a significant relationship between disease control rate with decrease in tumor markers (antigen 19-9, carcinoembyonic, and DUPAN-2). Patients who experienced a decrease of tumor markers tend to have better life expectancy.
Conclusion, the provision of weekly cycles of paclitaxel in patients with gemcitabine refractory pancreatic cancer who looks well-tolerated and effective. Paclitaxel therapy should be considered as salvage chemotherapy after failure of gemcitabine in patients with good performance status.
Xtreme Fat Loss Diet System!
No comments:
Post a Comment